Psychiatry Medical News about Schizophrenia Bipolar Disorder Asenapine

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Omega-3 fatty acids for bipolar disorder

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
Neuropsychiatric Disease and Treatment, 09/22/09

Bishara D et al. – Asenapine is a new atypical antipsychotic agent currently under development for the treatment of schizophrenia and bipolar disorder. Asenapine has shown efficacy in alleviating both positive and negative symptoms of schizophrenia compared with placebo. Although promising, further studies are required in order to determine whether it has advantages over placebo and other antipsychotics in alleviating cognitive impairment associated with schizophrenia. It has also shown long–term efficacy comparable with olanzapine in bipolar I disorder. Asenapine is generally well tolerated and appears to be metabolically neutral. It has low propensity to cause weight gain and prolactin elevation. There were no concerns in the studies about its effects on the cardiovascular system and QTc prolongation. The incidence of extrapyramidal symptoms with asenapine however has been found to be higher than that with olanzapine. It may be a useful alternative to aripiprazole in schizophrenia and bipolar disorder in patients who are at high risk of metabolic abnormalities.

<< Previous
What are the needs of alcohol dependent patients with a history...

Next >>
Growth in alcohol use in at-risk adolescent boys: Two-part random...

Study to probe bipolar, schizophrenia links
Internet Source, 10/21/09 Relevance Score: 82%

Schizophrenia and bipolar disorder: Bridging the divide
Internet Source, 10/20/09 Relevance Score: 82%

The P300 as a possible endophenotype for schizophrenia and bipolar disorder: Evidence from twin and patient studies
Psychiatry Research, 10/02/09 Relevance Score: 82%

Two-dimensional assessment of cytoarchitecture in the superior temporal white matter in schizophrenia, major depressive disorder and bipolar disorder
Schizophrenia Research, 10/28/09 Relevance Score: 81%

Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09 Relevance Score: 81%